Bayesian Methods in Pharmaceutical Research
-10%
portes grátis
Bayesian Methods in Pharmaceutical Research
Boulanger, Bruno; Lesaffre, Emmanuel; Baio, Gianluca
Taylor & Francis Ltd
04/2020
546
Dura
Inglês
9781138748484
15 a 20 dias
1170
Descrição não disponível.
I Introductory part
Chapter 1: Bayesian Background
Chapter 2: FDA Regulatory Acceptance of Bayesian Statistics
Chapter 3: Bayesian Tail Probabilities for Decision Making
II Clinical development
Chapter 4: Clinical Development in the Light of Bayesian Statistics
Chapter 5: Prior Elicitation
Chapter 6: Use of Historical Data
Chapter 7: Dose Ranging Studies and Dose Determination
Chapter 8: Bayesian Adaptive Designs in Drug Development
Chapter 9: Bayesian Methods for Longitudinal Data with Missingness
Chapter 10: Survival Analysis and Censored Data
Chapter 11: Benefit of Bayesian Clustering of Longitudinal Data: Study of Cognitive Decline for Precision Medicine
Chapter 12: Bayesian Frameworks for Rare Disease Clinical Development Programs
Chapter 13: Bayesian Hierarchical Models for Data Extrapolation and Analysis in Pediatric Disease Clinical Trials
III Post-marketing
Chapter 14: Bayesian Methods for Meta-Analysis
Chapter 15: Economic Evaluation and Cost-Effectiveness of Health Care Interventions
Chapter 16: Bayesian Modeling for Economic Evaluation Using "Real World Evidence"
Chapter 17: Bayesian Benefit-Risk Evaluation in Pharmaceutical Research
IV Product development and manufacturing
Chapter 18: Product Development and Manufacturing
Chapter 19: Process Development and Validation
Chapter 20: Analytical Method and Assay
Chapter 21: Bayesian Methods for the Design and Analysis of Stability Studies
Chapter 22: Content Uniformity Testing
Chapter 23: Bayesian methods for in vitro dissolution drug testing and similarity comparisons
Chapter 24: Bayesian Statistics for Manufacturing
V Additional topics
Chapter 25: Bayesian Statistical Methodology in the Medical Device Industry
Chapter 26: Program and Portfolio Decision-Making
Chapter 1: Bayesian Background
Chapter 2: FDA Regulatory Acceptance of Bayesian Statistics
Chapter 3: Bayesian Tail Probabilities for Decision Making
II Clinical development
Chapter 4: Clinical Development in the Light of Bayesian Statistics
Chapter 5: Prior Elicitation
Chapter 6: Use of Historical Data
Chapter 7: Dose Ranging Studies and Dose Determination
Chapter 8: Bayesian Adaptive Designs in Drug Development
Chapter 9: Bayesian Methods for Longitudinal Data with Missingness
Chapter 10: Survival Analysis and Censored Data
Chapter 11: Benefit of Bayesian Clustering of Longitudinal Data: Study of Cognitive Decline for Precision Medicine
Chapter 12: Bayesian Frameworks for Rare Disease Clinical Development Programs
Chapter 13: Bayesian Hierarchical Models for Data Extrapolation and Analysis in Pediatric Disease Clinical Trials
III Post-marketing
Chapter 14: Bayesian Methods for Meta-Analysis
Chapter 15: Economic Evaluation and Cost-Effectiveness of Health Care Interventions
Chapter 16: Bayesian Modeling for Economic Evaluation Using "Real World Evidence"
Chapter 17: Bayesian Benefit-Risk Evaluation in Pharmaceutical Research
IV Product development and manufacturing
Chapter 18: Product Development and Manufacturing
Chapter 19: Process Development and Validation
Chapter 20: Analytical Method and Assay
Chapter 21: Bayesian Methods for the Design and Analysis of Stability Studies
Chapter 22: Content Uniformity Testing
Chapter 23: Bayesian methods for in vitro dissolution drug testing and similarity comparisons
Chapter 24: Bayesian Statistics for Manufacturing
V Additional topics
Chapter 25: Bayesian Statistical Methodology in the Medical Device Industry
Chapter 26: Program and Portfolio Decision-Making
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
Prior Data Conflict;Cumulative Distribution Function;drug development;Predictive Probability Of Success;adaptive designs;Posterior Predictive Distribution;dose finding;Posterior Predictive Probability;meta-analysis;Posterior Distribution;survival analysis;Data Set;personalized medicine;Interim Analysis;Bayesian methods;MCMC Algorithm;Hierarchical Data Structure;Public health policies;Ich Q8;Pharmaceutical research;Predictive Probability;Bayesian biostatistics;Tolerance Interval;Predictive Distribution;HTA;Health Technology Assessments;Power Priors;Ich Q2;Sample Size Re-estimation;Medical Device Clinical Trials;Log Odds Ratios;Equal Tailed Credible Interval;Relative Treatment Effects;BNP;Bayesian Trial
I Introductory part
Chapter 1: Bayesian Background
Chapter 2: FDA Regulatory Acceptance of Bayesian Statistics
Chapter 3: Bayesian Tail Probabilities for Decision Making
II Clinical development
Chapter 4: Clinical Development in the Light of Bayesian Statistics
Chapter 5: Prior Elicitation
Chapter 6: Use of Historical Data
Chapter 7: Dose Ranging Studies and Dose Determination
Chapter 8: Bayesian Adaptive Designs in Drug Development
Chapter 9: Bayesian Methods for Longitudinal Data with Missingness
Chapter 10: Survival Analysis and Censored Data
Chapter 11: Benefit of Bayesian Clustering of Longitudinal Data: Study of Cognitive Decline for Precision Medicine
Chapter 12: Bayesian Frameworks for Rare Disease Clinical Development Programs
Chapter 13: Bayesian Hierarchical Models for Data Extrapolation and Analysis in Pediatric Disease Clinical Trials
III Post-marketing
Chapter 14: Bayesian Methods for Meta-Analysis
Chapter 15: Economic Evaluation and Cost-Effectiveness of Health Care Interventions
Chapter 16: Bayesian Modeling for Economic Evaluation Using "Real World Evidence"
Chapter 17: Bayesian Benefit-Risk Evaluation in Pharmaceutical Research
IV Product development and manufacturing
Chapter 18: Product Development and Manufacturing
Chapter 19: Process Development and Validation
Chapter 20: Analytical Method and Assay
Chapter 21: Bayesian Methods for the Design and Analysis of Stability Studies
Chapter 22: Content Uniformity Testing
Chapter 23: Bayesian methods for in vitro dissolution drug testing and similarity comparisons
Chapter 24: Bayesian Statistics for Manufacturing
V Additional topics
Chapter 25: Bayesian Statistical Methodology in the Medical Device Industry
Chapter 26: Program and Portfolio Decision-Making
Chapter 1: Bayesian Background
Chapter 2: FDA Regulatory Acceptance of Bayesian Statistics
Chapter 3: Bayesian Tail Probabilities for Decision Making
II Clinical development
Chapter 4: Clinical Development in the Light of Bayesian Statistics
Chapter 5: Prior Elicitation
Chapter 6: Use of Historical Data
Chapter 7: Dose Ranging Studies and Dose Determination
Chapter 8: Bayesian Adaptive Designs in Drug Development
Chapter 9: Bayesian Methods for Longitudinal Data with Missingness
Chapter 10: Survival Analysis and Censored Data
Chapter 11: Benefit of Bayesian Clustering of Longitudinal Data: Study of Cognitive Decline for Precision Medicine
Chapter 12: Bayesian Frameworks for Rare Disease Clinical Development Programs
Chapter 13: Bayesian Hierarchical Models for Data Extrapolation and Analysis in Pediatric Disease Clinical Trials
III Post-marketing
Chapter 14: Bayesian Methods for Meta-Analysis
Chapter 15: Economic Evaluation and Cost-Effectiveness of Health Care Interventions
Chapter 16: Bayesian Modeling for Economic Evaluation Using "Real World Evidence"
Chapter 17: Bayesian Benefit-Risk Evaluation in Pharmaceutical Research
IV Product development and manufacturing
Chapter 18: Product Development and Manufacturing
Chapter 19: Process Development and Validation
Chapter 20: Analytical Method and Assay
Chapter 21: Bayesian Methods for the Design and Analysis of Stability Studies
Chapter 22: Content Uniformity Testing
Chapter 23: Bayesian methods for in vitro dissolution drug testing and similarity comparisons
Chapter 24: Bayesian Statistics for Manufacturing
V Additional topics
Chapter 25: Bayesian Statistical Methodology in the Medical Device Industry
Chapter 26: Program and Portfolio Decision-Making
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
Prior Data Conflict;Cumulative Distribution Function;drug development;Predictive Probability Of Success;adaptive designs;Posterior Predictive Distribution;dose finding;Posterior Predictive Probability;meta-analysis;Posterior Distribution;survival analysis;Data Set;personalized medicine;Interim Analysis;Bayesian methods;MCMC Algorithm;Hierarchical Data Structure;Public health policies;Ich Q8;Pharmaceutical research;Predictive Probability;Bayesian biostatistics;Tolerance Interval;Predictive Distribution;HTA;Health Technology Assessments;Power Priors;Ich Q2;Sample Size Re-estimation;Medical Device Clinical Trials;Log Odds Ratios;Equal Tailed Credible Interval;Relative Treatment Effects;BNP;Bayesian Trial
